

# Maria Martinez-Garcia

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/426631/publications.pdf>

Version: 2024-02-01

13  
papers

498  
citations

933264

10  
h-index

1125617

13  
g-index

13  
all docs

13  
docs citations

13  
times ranked

991  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Comparison of RNA-Seq Results from Paired Formalin-Fixed Paraffin-Embedded and Fresh-Frozen Glioblastoma Tissue Samples. PLoS ONE, 2017, 12, e0170632.	1.1	100
2	NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival. Clinical Cancer Research, 2019, 25, 1535-1545.	3.2	86
3	First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors. Clinical Cancer Research, 2018, 24, 1536-1545.	3.2	76
4	First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors. Clinical Cancer Research, 2016, 22, 877-885.	3.2	59
5	Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer. Investigational New Drugs, 2018, 36, 848-859.	1.2	55
6	Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity. Clinical Cancer Research, 2017, 23, 5406-5415.	3.2	29
7	Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifestuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer. Clinical Cancer Research, 2020, 26, 364-372.	3.2	29
8	High Numbers of Circulating CD57+ NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2+ Primary Breast Cancer. Cancer Immunology Research, 2019, 7, 1280-1292.	1.6	25
9	A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer. ESMO Open, 2019, 4, e000532.	2.0	13
10	Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy. Clinical Cancer Research, 2020, 26, 6600-6609.	3.2	10
11	Vanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsies. Translational Oncology, 2021, 14, 100984.	1.7	9
12	RNA sequencing and Immunohistochemistry Reveal ZFN7 as a Stronger Marker of Survival than Molecular Subtypes in G-CIMP-negative Glioblastoma. Clinical Cancer Research, 2021, 27, 645-655.	3.2	5
13	SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021). Clinical and Translational Oncology, 2022, 24, 703-711.	1.2	2